drugset / Trial / NCT04541173
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase 2
Terminated
6 enrolled
Aiwu Ruth He, MD
Genentech, Inc. · collabGeorgetown University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.
Timeline
- Start
- 2020-11-30
- Primary completion
- 2023-06-18
- Completion
- 2023-06-30
Outcome
Outcome not reported
Stopped (Enrollment): “Due to slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |